




RealRate

# PHARMACEUTICAL 2018

Onconova Therapeutics Inc.  
Rank 328 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence • [www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of Onconova Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Onconova Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 194% points. The greatest weakness of Onconova Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 517% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,054%, being 776% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	4,903
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,976
Liabilities, Non-Current	0
Other Assets	12
Other Compr. Net Income	34
Other Expenses	-1,615
Other Liabilities	5,864
Other Net Income	30
Property and Equipment	64
Research and Development	19,119
Revenues	787
Selling, General and Administrative Expense	7,405

Output Variable	Value in 1000 USD
Assets	4,979
Liabilities	15,840
Expenses	24,909
Stockholders Equity	-10,861
Net Income	-24,092
Comprehensive Net Income	-24,075
Economic Capital Ratio	-1,054%